Indication
Acute Leukemias of Ambiguous Lineage
1 clinical trial
4 drugs
Clinical trial
S1312, A Phase I Study of Inotuzumab Ozogamicin (NSC-772518) in Combination With CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients With Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia, and Burkitt's Leukemia)Status: Completed, Estimated PCD: 2022-01-01
Drug
cyclophosphamideDrug
VincristineDrug
prednisone